Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

There has been increased interest in hypofractionated accelerated chemoradiation for head and neck cancer during the recent first peak of the COVID-19 pandemic. Prospective data regarding this approach from randomised trials is lacking. In the PET NECK study, 564 patients with squamous cell carcinom...

Full description

Bibliographic Details
Main Authors: Dunn, J. (Author), Fong, C. (Author), Hartley, A. (Author), Mehanna, H. (Author), Sanghera, P. (Author), Vreugdenhil, M. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2021
Subjects:
adult
aged
Aged
Article
cancer control
cancer survival
capecitabine
carboplatin
Carcinoma, Squamous Cell
cetuximab
chemoradiotherapy
Chemoradiotherapy
cisplatin
clinical effectiveness
coronavirus disease 2019
COVID 19
COVID-19
epidemiology
female
Female
follow up
Follow-Up Studies
Fractionation
Head and neck cancer
Head and Neck Neoplasms
head and neck squamous cell carcinoma
head and neck tumor
human
Humans
Hypofractionated chemoradiation
hypofractionated radiotherapy
intensity modulated radiation therapy
major clinical study
male
Male
methotrexate
middle aged
Middle Aged
neck dissection
Neck Dissection
outcome assessment
overall survival
pandemic
Pandemic
Pandemics
platinum derivative
Positron Emission Tomography Computed Tomography
positron emission tomography-computed tomography
priority journal
procedures
prospective study
quality of life
Quality of Life
radiation dose
Radiation Dose Hypofractionation
randomized controlled trial (topic)
SARS-CoV-2
squamous cell carcinoma
treatment outcome
Treatment Outcome
virology
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items